Rovalpituzumab Tesirine Is Active in Patients with DLL3-Positive Tumors.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2016-232
Abstract: Rovalpituzumab tesirine is well tolerated and has single-agent antitumor activity. read more here.
Keywords: patients dll3; positive tumors; rovalpituzumab tesirine; dll3 positive ... See more keywords